Abstract
Cancer stem cells (CSCs) are a small subset of cells in cancers that are thought to initiate tumorous transformation and promote metastasis, recurrence, and resistance to treatment. Growing evidence has revealed the existence of CSCs in various types of cancers and suggested that CSCs differentiate into diverse lineage cells that contribute to tumor progression. We may be able to overcome the limitations of cancer treatment with a comprehensive understanding of the biological features and mechanisms underlying therapeutic resistance in CSCs. This review provides an overview of the properties, biomarkers, and mechanisms of resistance shown by CSCs. Recent findings on metabolic features, especially fatty acid metabolism and ferroptosis in CSCs, are highlighted, along with promising targeting strategies. Targeting CSCs is a potential treatment plan to conquer cancer and prevent resistance and relapse in cancer treatment.
Introduction
Conventional cancer treatments, such as chemotherapy and radiation, primarily target rapidly dividing "bulk" tumor cells. While these therapies often achieve initial success, tumors frequently recur due to the survival of cancer stem cells (CSCs). These cells possess unique stem-like qualities, including self-renewal and the ability to differentiate into diverse cell lineages, making them the "seeds" of metastasis and the "roots" of recurrence. Understanding the biological mechanisms that allow CSCs to survive treatment is critical for developing therapies that can permanently eradicate cancer.
Immunological Evasion and the Tumor Microenvironment
CSCs have evolved sophisticated methods to hide from the host's immune system. They manipulate surface molecules to evade detection by Natural Killer (NK) cells and Cytotoxic T Lymphocytes (CTLs). A key mechanism involves the overexpression of "don't eat me" signals, such as CD47 and SIRPγ, which inhibit macrophage phagocytosis.
Beyond individual cell signaling, CSCs actively shape their surrounding niche. They recruit immunosuppressive cells, including Myeloid-Derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs), to create a protective environment that shields them from immune attack. This crosstalk between CSCs and the tumor microenvironment (TME) is a primary driver of therapeutic resistance.
Metabolic Plasticity and the Ferroptosis Paradox
One of the most striking features of CSCs is their metabolic adaptability. Unlike bulk tumor cells that often rely on glycolysis (the Warburg Effect), CSCs can switch between glycolysis and oxidative phosphorylation (OXPHOS) depending on nutrient availability. They frequently utilize fatty acid oxidation (FAO) to survive in nutrient-deprived conditions, making enzymes like FASN and SREBP-1 potential therapeutic targets.
Furthermore, CSCs exhibit a complex relationship with ferroptosis, an iron-dependent form of regulated cell death. While ferroptosis induction is a promising strategy to kill CSCs, many have developed resistance by upregulating the SLC7A11/GPX4 axis to neutralize lipid peroxides. Targeting this antioxidant defense system is a major focus for sensitizing CSCs to treatment.
Therapeutic Strategies and Future Directions
Recent research has identified several promising avenues for targeting CSCs:
- Immunotherapy: CAR-T cells targeting markers like CD133, EpCAM, and CD19 are currently in early-phase clinical trials.
- Overcoming Radio-resistance: Inhibiting the JAK2/STAT3/CCND2 axis or DNA repair proteins (e.g., RAD51) can sensitize CSCs to radiotherapy.
- Reversing Chemo-resistance: Small-molecule inhibitors targeting ABC transporters and the Notch1/ABCG2 pathway are being evaluated to prevent drug efflux.
Despite these advances, challenges remain. Many CSC markers are also present on healthy adult stem cells, raising concerns about off-target toxicity. Future efforts must focus on improving biomarker specificity and utilizing nanotechnology for precise drug delivery to the CSC niche. By integrating metabolic and immunologic targeting, researchers hope to move beyond tumor shrinkage toward complete cancer eradication.
Summary updated